5-Bromo-2-Hydroxy-3-Picoline | CAS:89488-30-2

We serve 5-Bromo-2-Hydroxy-3-Picoline CAS:89488-30-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
5-Bromo-2-Hydroxy-3-Picoline

Chemical Name:5-Bromo-2-Hydroxy-3-Picoline
CAS.NO:89488-30-2
Synonyms:5-Bromo-2-Hydroxy-3-Picoline
5-bromo-3-methyl-1H-pyridin-2-one
5-bromo-3-methylpyridin-2-ol
5-Bromo-3-methylpyridin-2(1H)-one
 
Physical and Chemical Properties:
Density 1.7±0.1 g/cm3
Boiling Point 326.2±37.0 °C at 760 mmHg
Melting Point 170-174 °C(lit.)
Molecular Formula C6H6BrNO
Molecular Weight 188.022
Flash Point 151.1±26.5 °C
 
Specification:
Appearance:Off-white solid
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 5-Bromo-2-Hydroxy-3-Picoline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Bromo-3-methylpyridin-2(1H)-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-bromo-3-methyl-1H-pyridin-2-one Use and application,5-bromo-3-methylpyridin-2-ol technical grade,usp/ep/jp grade.


Related News: Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.’s governing body.tetradecane-1-thiol manufacturer The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.1-Fluoro-2-nitrobenzene supplier An active pharmaceutical ingredient (API) is a substance, or a mixture of ingredients, combined in the manufacture of a pharmaceutical or drug.4-Chloropyrrolo[2,3-d]pyrimidine vendor An active pharmaceutical ingredient (API) is a substance, or a mixture of ingredients, combined in the manufacture of a pharmaceutical or drug.The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.